• Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

    来源: Nasdaq GlobeNewswire / 14 3月 2024 15:15:00   America/Chicago

    N/A
分享